Research & Development
Breast Cancer: Page 2
BPGbio expands agreement with DoD on AI-guided breast cancer diagnostic panel
The diagnostic panel was developed using artificial intelligence to identify patients diagnosed with ER+ breast cancer who do not respond to hormone therapy, to guide caregivers to appropriate treatment options.
May 24, 2023
Thermo Fisher Scientific, Pfizer collaborate to broaden NGS testing in underserved countries
Under the agreement, Thermo Fisher will select local labs for its NGS technology, ensuring they have the infrastructure, trained staff, and quality control measures to meet industry standards to conduct NGS testing for breast and lung cancer.
May 9, 2023
PreludeDx obtains CMS advanced approval for DCIS test
The CMS approval, effective April 1, confirms that the test meets specific criteria established for laboratory tests under the Protecting Access to Medicare Act of 2014 (PAMA).
March 28, 2023
Protein expression biomarker may identify likely responders to potential breast cancer drug
In a study, researchers sought to understand the value of RANK and RANKL protein expression as a predictor of breast cancer outcomes and as a therapeutic target.
March 8, 2023
Agendia MammaPrint UltraLow Risk gene signature recognized in updated NCCN guidelines
The MammaPrint 70-gene signature identifies patients at low or high risk of distant recurrence within five years of a breast cancer diagnosis.
February 13, 2023
New York State Department of Health approves PreciseDx breast cancer LDT
With the approval, PreciseDx can begin testing patient samples using its PDxBr test in the state of New York through its CLIA-certified laboratory.
February 7, 2023
Guardant360 CDx breast cancer liquid biopsy test receives FDA approval as companion diagnostic
The Guardant360 CDx blood test uses genomic profiling to identify patients with ESR1 mutations who may benefit from Orserdu therapy.
January 30, 2023
Bionano Genomics announces study findings on optical genome mapping
A study using Bionano Genomics’ OGM shows the method is able to identify homologous recombination deficiency (HRD) in breast cancer samples.
January 13, 2023
Menarini study demonstrates impact of circulating tumor cell counting on metastatic breast cancer survival
The data demonstrated that a single assessment of circulating tumor cell count by CellSearch before treatment commences may lead to increased overall survival in patients with metastatic breast cancer.
December 22, 2022
Molecular signature in study sheds light on adjuvant radiation therapy after breast-conserving surgery
Low scores on an investigational gene molecular signature suggest similar rates of local recurrence whether or not patients received adjuvant radiation therapy after breast-conserving surgery.
December 9, 2022
Exact Sciences shares validation data for breast cancer radiation signature at SABCS
The data presented as part of SABCS’s press program were from a meta-analysis of three independent, randomized clinical trials that identified which early-stage breast cancer patients benefited from radiotherapy after breast-conserving surgery.
December 12, 2022
PathomIQ presents data on AI predictive model at SABCS
The model predicts the response to neoadjuvant chemotherapy in patients with triple-negative breast cancer through extracting morphological features.
December 8, 2022
Page 2 of 12